Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**RENOVITE BMP-2** is Renovos' injectable, synthetic nanoclay-based bone-fusion gel that locally retains and delivers bone morphogenetic protein 2 to promote osteogenesis and targeted bone formation. It is being developed as an alternative to conventional bone-graft materials for interbody spinal fusion; the biodegradable nanoclay carrier is intended to remain at the injection site, support cellular infiltration, and be gradually replaced by regenerated bone. The product received FDA Breakthrough Device Designation in January 2024. ([renovos.co.uk](https://www.renovos.co.uk/renovos-biologics-receives-fda-breakthrough-device-designation/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RENOVITE BMP-2.